Recent Updates
Recently added Catalysts

V118C

Phase 1

Healthy | Monoclonal antibody | Other |Merck & Company, Inc.|Last Updated: Jan 20, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials1
Total Enrollment65
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06611033A Study of V118 Formulation C (V118C) in Healthy Participants (V118C-001)PHASE1 COMPLETED 65Sep 25, 2024Jan 9, 2026Jan 20, 20263 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants with Solicited Injection Site Adverse Events (AEs)
Up to approximately 7 days after each vaccination

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. The number of participants with a solicited injection-site AE will be reported.

Number of Participants with Solicited Systemic AEs
Up to approximately 7 days after each vaccination

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. The number of participants with a solicited systemic AE will be reported.

Number of Participants with Immediate AEs Following Vaccination
Up to approximately 30 minutes after each vaccination

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. The number of participants with Immediate AEs following vaccination will be reported.

Number of Participants with Unsolicited AEs
Up to approximately 28 days after each vaccination

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. An unsolicited AE is an AE that is not solicited using a vaccine report card (VRC) and that is communicated by a participant. The number of participants that experienced an unsolicited AE will be reported.

Number of Participants With a Serious Adverse Event (SAE)
Up to approximately 12 months after final vaccination

An SAE is defined as any untoward medical occurrence that at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect. The number of participants who experience an SAE will be reported.

Number of Participants with a Medically Attended Adverse Event (MAAE)
Up to approximately 12 months after final vaccination

An MAAE is defined as an adverse event in which medical attention is received during an unscheduled, non-routine outpatient visit, such as an emergency room visit, office visit, or an urgent care visit with any medical personnel for any reason. The number of participants who experience an MAAE will be reported.

Number of Participants with an Event of Clinical Interest (ECI)
Up to approximately 12 months after final vaccination

An ECI includes but is not limited to: 1) An overdose defined as: A participant receiving more than 1 dose of study vaccine in a 24-hour period or more than 2 doses of study vaccine throughout the study. 2) Potential drug-induced liver injury (DILI) events defined as: An elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) lab value that is ≥3 times the upper limit of normal (ULN) and an elevated total bilirubin lab value that is ≥2 times ULN and, at the same time, an alkaline phosphatase lab value that is \<2 times ULN, as determined by way of protocol-specified laboratory testing or unscheduled laboratory testing. 3) Potential immune-mediated disease (pIMDs) defined as: A subset of AEs that include either an established autoimmune disease(s) or Inflammatory and/or neurologic disorder(s), which might or might not have an autoimmune etiology. The number of participants who experience an ECI will be reported.

Secondary Endpoints
Serotype-specific Immunoglobulin G (IgG) geometric mean concentrations (GMCs)
Day 28 postvaccination
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeBASIC_SCIENCE
Treatment Arms
ArmTypeDescription
V118CEXPERIMENTALParticipants receive intramuscular (IM) injection of V118C in a 2-dose regimen administered on Day 1 and Day 29.
V118EXPERIMENTALParticipants receive IM injection of V118 in a 2-dose regimen administered on Day 1 and Day 29.
PREVNAR 20™ + SalineACTIVE_COMPARATORParticipants receive one dose of IM injection of PREVNAR 20™ in a 2-dose regimen on Day 1 followed by one dose of saline on Day 29.
Interventions
NameTypeDescription
V118CBIOLOGICALIntramuscular Administration
V118BIOLOGICALIntramuscular Administration
PREVNAR 20™BIOLOGICALIntramuscular Administration
SalineBIOLOGICALIntramuscular Administration
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 49 Years
SexALL
Healthy VolunteersYes
Study Sites3

The main inclusion criteria include but are not limited to the following: * Is in good health before randomization Exclusion Criteria: * Has a history of invasive pneumococcal disease or known history of other culture-positive pneumococcal disease within 3 years prior to receiving study vaccinati...

Countries:United States
Unlock Eligibility Criteria